SDGR

Schrodinger, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001490978 Biotech & Drug Discovery

$24.47 +0.67 (+2.82%)

Oct 26 4:00 PM ET · prev $23.80

Market cap

$1.7B

Small cap

Consensus

Buy

77% Buy or better · 13 analysts

Median target

$30.00

+23% · range $17.00–32.00

Next earnings

Nov 4

in 9 days

1 year

+10.4%

from $22.17 · Oct 27

30 days

−17.1%

from $29.50

52-week range

$11.07–32.60

−25% from high · low Mar 30

Avg volume 20D

2.54M

shares / day

Short interest

10.13M

≈13.5% of shares · −9.3%

Days to cover

3.1

at average volume

Insider net

−$2.3M

0 buyers · 7 sellers · since Mar 2

New fund stakes

Q2 2026 13F · 0 exits

SecBot read BULLISH 1 report · latest

Balance 0 bearish · 1 bullish oldest → newest, height = score

Avg score

·High conf. 1/1 ·Next Earnings date, Nov 4, 2026

Strongest BULLISH Schrodinger received an approximately $57 million cash payment from Eli Lilly's acquisition of Ajax…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Feb 25 Schrodinger reported strong full-year 2025 financial results with to…
S Mar 2 to Mar 6 4 days of insider sells: $242.8K by 7 insiders, avg $12.50
S Apr 16 to Apr 17 2 days of insider sells: $1.1M by 2 insiders, avg $12.27
R Apr 16 Schrodinger CEO Farid Ramy sold $530,233 worth of shares in an open-…
R Jun 29 Schrodinger received an approximately $57 million cash payment from…
S Jul 16 1 insider sell $13.6K at $15.60
S Sep 17 1 insider sell $928.0K at $29.37

Signal stack

Where each data set points today.

InsidersBEARISH

7 insiders sold $2.3M.
InstitutionsBULLISH

Q2 2026: 29 added (0 new), 12 trimmed or exited.
AnalystsBULLISH

10 of 13 rate it Buy or better. Median target $30.00 (+23%).
Short sellersSTEADY

Short interest −9.3% to 10.13M shares. 3.1 days to cover, ≈13.5% of shares.
TrendRANGE

1% above its 50-day average.
SocialQUIET

No Reddit mentions this week. Last mention Oct 9.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
UBS Group AG	TRIM	964,129	$15.7M
CITADEL ADVISORS LLC	DOUBLED	895,780	$14.6M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	TRIM	866,942	$14.1M
DIMENSIONAL FUND ADVISORS LP	TRIM	636,367	$10.3M
Nuveen, LLC	DOUBLED	614,314	$10.0M
TUDOR INVESTMENT CORP ET AL	TRIM	409,086	$6.6M
Jump Financial, LLC	ADD	326,500	$5.3M
ExodusPoint Capital Management, LP	ADD	296,517	$4.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts

Buy 77% rate it Buy or better

Strong Buy3Buy7Hold3Sell0Strong Sell0

12-month targets · 7 analysts

$24.47 $17.00 $30.00 $32.00

Price is inside the target range. Median implies +23%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 20, 2026	UBS MAINTAIN	MAINTAIN	Neutral
Oct 16, 2026	Keybanc MAINTAIN	MAINTAIN	Overweight
Oct 13, 2026	TD Cowen MAINTAIN	MAINTAIN	Buy
Oct 12, 2026	BMO Capital MAINTAIN	MAINTAIN	Outperform
May 14, 2026	Morgan Stanley MAINTAIN	MAINTAIN	Equal-Weight

Insider ledger

Form 4

bought · 0 insiders

$2.3M

sold · 7 insiders

Date	Insider	Type	Value
Sep 17, 2026	Akinsanya Karen See Remarks	EXERCISE	$137.1K
Sep 17, 2026	Akinsanya Karen See Remarks	SELL	$280.0K
Sep 17, 2026	Akinsanya Karen See Remarks	SELL	$648.0K
Jul 16, 2026	Jain Rachit EVP & CFO	SELL	$13.6K
Jun 26, 2026	Friesner Richard Director	GIFT	679,373 sh
Jun 22, 2026	Thornberry Nancy Director	AWARD	8,141 sh
Jun 22, 2026	van Kralingen Bridget A Director	AWARD	13,313 sh
Jun 22, 2026	Sender Gary Director	AWARD	8,141 sh

Earnings setup

Estimates

Nov 4

reports in 9 days

Revision history: 🔒 Fresh data, subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data, subscribers only
Next Q	-$0.20	-$0.32–-$0.05	+0.0%	$74.7M
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only